Cabozantinib
- Generic Name
- Cabozantinib
- Brand Names
- Cabometyx, Cometriq
- Drug Type
- Small Molecule
- Chemical Formula
- C28H24FN3O5
- CAS Number
- 849217-68-1
- Unique Ingredient Identifier
- 1C39JW444G
- Background
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...
- Indication
⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。
⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
- Associated Therapies
- -
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
- Conditions
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06132945
- Locations
- 🇺🇸
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT06026410
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
🇺🇸University of Southern California, Los Angeles, California, United States
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
- Conditions
- Interventions
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Jun Zhang, MD, PhD
- Target Recruit Count
- 40
- Registration Number
- NCT05859217
- Locations
- 🇺🇸
The University of Kansas Cancer Center - Westwood, Kansas City, Kansas, United States
🇺🇸The University of Kansas Cancer Center - Indian Creek, Overland Park, Kansas, United States
🇺🇸The University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT05836571
- Locations
- 🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
- Conditions
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT05663710
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Target Recruit Count
- 41
- Registration Number
- NCT05660954
- Locations
- 🇪🇸
Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain
🇪🇸Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 33
- Registration Number
- NCT05613894
- Locations
- 🇺🇸
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 302
- Registration Number
- NCT05536141
- Locations
- 🇺🇸
Tisch Cancer Institute, Icahn Mount Sinai Hospital, New York, New York, United States
🇦🇺Ashford Cancer Centre Research/ICON, Sydney, Australia
🇺🇸UCLA, Santa Monica, California, United States
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Rana McKay, MD
- Target Recruit Count
- 50
- Registration Number
- NCT05502315
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of California San Diego, La Jolla, California, United States
Cabozantinib for Patients With Recurrent or Progressive Meningioma
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Baptist Health South Florida
- Target Recruit Count
- 24
- Registration Number
- NCT05425004
- Locations
- 🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.